Susan Galbraith, AstraZeneca EVP, oncology R&D

Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body

Look­ing to ex­pand its on­col­o­gy pipeline, As­traZeneca has turned to the east to pick up a next-gen drug against an emerg­ing tar­get.

Har­bour Bio­Med, a Shang­hai-based out­fit that al­so has siz­able teams in Cam­bridge, MA and Rot­ter­dam, Nether­lands, is out-li­cens­ing its CLDN18.2xCD3 bis­pe­cif­ic an­ti­body to As­traZeneca in ex­change for $25 mil­lion up­front and up to $325 mil­lion in mile­stones plus roy­al­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.